I this presentation, I present pharma social media “milestones” or “firsts” that have paved the way for others to follow and identify the “Pioneers” who have helped the industry navigate through “uncharted” territory lacking regulatory guidance.
I also review some “mistakes” made by both leaders and followers. Only those who learn from the mistakes of their competitors will move forward. Those who learn from their OWN mistakes will move forward fastest!
Finally, I offer some ideas for “best practices” and “guiding principles” that may help pharma avoid regulatory actions.
Pharma Marketing Blog 2010: The Year in ImagesPharma Guy
The document provides images and captions from the Pharma Marketing Blog in 2010. It discusses topics such as social media use by pharmaceutical companies, FDA regulation of online activities, direct-to-consumer advertising trends, and payments made by pharmaceutical companies to physicians. The images show charts, graphs and screenshots illustrating these topics from the blog over the course of the year.
Pharma Marketing Blog: The Year 2013 in ImagesPharma Guy
This document provides summaries of 13 images from the Pharma Marketing Blog in 2013. The images highlight topics such as: declining direct-to-consumer advertising spending; the potential for biologics to surpass small molecule drugs in sales; challenges for pharma companies in using social media and mobile technologies; and regulatory actions against pharmaceutical companies.
Importance of social media in Pharmaceutical industryActiance, Inc.
Guidelines for the pharmaceutical industry are lacking, Novartis had used Facebook and two popular social networking sites, to influence consumers in spreading the word about Tasigna, a cancer drug. The FDA concluded that Novartis’ act failed to meet regulatory and compliance standards. Specifically, the FDA called out Novartis’ marketing as incomplete and misleading since it failed to communicate any risk information associated with the use of Tasigna.
The impact of social media on the pharmaceutical sectorPaul Grant
A presentation delivered to an audience of medical information, researchers, and clinical trial colleagues from within the pharmaceutical industry at the DIA Clinical Forum in Basel, 12th October 2011
Pharma, Social Media, & Mobile A Happy Ménage à Trois?Pharma Guy
The document discusses pharmaceutical companies' use of social media and mobile applications. It notes milestones and mistakes in pharma's adoption of these technologies. It also summarizes guidelines from regulatory agencies on topics like adverse event reporting, off-label promotion, and editing drug information online. Survey results show most agree self-regulation is needed for mobile medical apps. The document provides resources for assessing social media readiness and best practices in mobile health.
Faisal Ahmed is interviewed about his background in digital marketing and views on social media and its use in pharma. He has over 14 years experience in digital, including roles at Amazon and launching multimedia games websites. For the past 3 years, he has worked in healthcare. He defines social media as having evolved into social amplifiers like Facebook and content sites like Tumblr. In pharma, social media is mainly used for PR with a push message rather than interaction. The biggest mistake companies make is not considering the end user perspective. The future of digital marketing will be driven by increasing smartphone usage and 4G enabling more powerful applications.
Patients Rising: How to Reach Empowered, Digital Health Consumerse-Patient Connections
Kru Research's white paper discussing how to reach out to empowered, digital, health consumers or e-Patients. Discussion of participatory medicine, digital health consumers, e-Patients, web 2.0, the power of social media, ROI of social media, regulatory concerns, HIPAA, FDA, adverse event reporting, and the future of social media in health marketing.
Pharma Marketing Blog 2010: The Year in ImagesPharma Guy
The document provides images and captions from the Pharma Marketing Blog in 2010. It discusses topics such as social media use by pharmaceutical companies, FDA regulation of online activities, direct-to-consumer advertising trends, and payments made by pharmaceutical companies to physicians. The images show charts, graphs and screenshots illustrating these topics from the blog over the course of the year.
Pharma Marketing Blog: The Year 2013 in ImagesPharma Guy
This document provides summaries of 13 images from the Pharma Marketing Blog in 2013. The images highlight topics such as: declining direct-to-consumer advertising spending; the potential for biologics to surpass small molecule drugs in sales; challenges for pharma companies in using social media and mobile technologies; and regulatory actions against pharmaceutical companies.
Importance of social media in Pharmaceutical industryActiance, Inc.
Guidelines for the pharmaceutical industry are lacking, Novartis had used Facebook and two popular social networking sites, to influence consumers in spreading the word about Tasigna, a cancer drug. The FDA concluded that Novartis’ act failed to meet regulatory and compliance standards. Specifically, the FDA called out Novartis’ marketing as incomplete and misleading since it failed to communicate any risk information associated with the use of Tasigna.
The impact of social media on the pharmaceutical sectorPaul Grant
A presentation delivered to an audience of medical information, researchers, and clinical trial colleagues from within the pharmaceutical industry at the DIA Clinical Forum in Basel, 12th October 2011
Pharma, Social Media, & Mobile A Happy Ménage à Trois?Pharma Guy
The document discusses pharmaceutical companies' use of social media and mobile applications. It notes milestones and mistakes in pharma's adoption of these technologies. It also summarizes guidelines from regulatory agencies on topics like adverse event reporting, off-label promotion, and editing drug information online. Survey results show most agree self-regulation is needed for mobile medical apps. The document provides resources for assessing social media readiness and best practices in mobile health.
Faisal Ahmed is interviewed about his background in digital marketing and views on social media and its use in pharma. He has over 14 years experience in digital, including roles at Amazon and launching multimedia games websites. For the past 3 years, he has worked in healthcare. He defines social media as having evolved into social amplifiers like Facebook and content sites like Tumblr. In pharma, social media is mainly used for PR with a push message rather than interaction. The biggest mistake companies make is not considering the end user perspective. The future of digital marketing will be driven by increasing smartphone usage and 4G enabling more powerful applications.
Patients Rising: How to Reach Empowered, Digital Health Consumerse-Patient Connections
Kru Research's white paper discussing how to reach out to empowered, digital, health consumers or e-Patients. Discussion of participatory medicine, digital health consumers, e-Patients, web 2.0, the power of social media, ROI of social media, regulatory concerns, HIPAA, FDA, adverse event reporting, and the future of social media in health marketing.
Examine why hospitals may want to consider a more comprehensive plan in using social media before hopping on Facebook. If you are already on Facebook examine the issues and re-strategize.
Every business needs to be on social media these days. However, social media can be legally risky if done wrong! Learn five top tips to keep your business from getting sued while using social media for marketing.
The document discusses the growing use of social networks in the healthcare industry for sharing health information. It outlines four types of healthcare social networks: those founded by individuals to discuss specific diseases, those run by nonprofit organizations, those created by startup companies, and those started by established healthcare/pharmaceutical corporations. The challenges of corporate involvement are addressed, such as managing off-label promotion and adverse event reporting. Transparency, privacy, and not competing with existing networks are recommended.
This document summarizes a research study analyzing the impact of social media on employment. The study surveyed 200 employees and student athletes about their social media use, privacy settings, and views on employers monitoring accounts. The introduction discusses how employers are increasingly viewing social media to make hiring decisions. The literature review summarizes several sources discussing both positive and negative consequences of social media use in the workplace. The justification section argues that as social media becomes more integrated into personal and professional life, users must be aware that online content can affect future employment opportunities.
The document discusses the evolving role of social media and web-based adverse event reporting in pharmacovigilance. It argues that current drug safety regulations were developed when data was scarce, but we now live in a world of abundant safety data due to digitization of healthcare information. New business models for drug safety are possible through dramatically lower costs of collecting and reporting safety data. However, our old regulatory concepts clash with this new environment. The document suggests designating social media information as a public good and formulating new rules and report types to better govern drug safety in this digital world.
The document discusses regulation of the internet and social media by the FDA. It argues that the current regulatory approach has become obsolete given changes in communication technologies. While the FDA aims to protect public health, its actions have disrespected free speech and shown a lack of understanding of new media. The document recommends that the FDA take time to understand how consumers actually use the internet for health information before making evidence-based policy decisions. It also suggests partnering with technology companies and incorporating advisory committees to develop guidance better suited to the fast-paced social media environment.
The document summarizes feedback from stakeholders on AstraZeneca's submission to the FDA regarding social media engagement in the pharmaceutical industry.
Key discussion points included that social media is important for advancing public health, and pharmaceutical companies have a responsibility to engage more in social media. Stakeholders provided feedback on the FDA's role as regulator, noting social media requires a tailored approach, and companies can help address misinformation online. They also covered pharmaceutical companies' role, emphasizing the need for ongoing dialogue and mutual agreement with patients/caregivers.
The thoughts of patients, health advocates, former government officials, bloggers and others who participated in a roundtable discussion that AstraZeneca convened in 2010.
This document summarizes feedback from stakeholders on AstraZeneca's submission to the FDA regarding social media engagement in the pharmaceutical industry. Key discussion points included that social media is important for advancing public health and that pharmaceutical companies have a responsibility to engage more in social media. Regarding the FDA, stakeholders felt they should recognize social media as a unique forum requiring tailored regulation and work more closely with industry. For pharmaceutical companies, stakeholders emphasized the importance of ongoing dialogue with patients/caregivers and ensuring mutual agreement and benefit from social media engagement.
In late 2011, the FDA released a document addressing how the pharmaceutical industry can and should respond to requests about off-label drug usage. This POV provides more information about the guidance document, highlights the key issues, and offers use cases to consider in the digital realm.
Social Media Guidelines and Safeguards for the Phamaceutical Industry: What Y...Stacy Lukasavitz Steele
This is a POV I wrote in June 2010 advising pharmaceutical companies on what they should do in the social media space until the FDA issues its official guidelines. It will soon be updated.
Healthcare marketers understand the value of social media, but may not feel prepared to participate in such a tightly regulated space. How can you join the conversation while protecting your organization? With these five documents, you can safely enter the world of social media while reducing your liability and maintaining a consistent company message.
Visit us at www.GreyMatterMarketing.com
Point of view of the recently released draft guidance for industry for pharma and social media by Navicor - an Oncology focused marketing and communications company.
1. Social media is changing how health information is shared, as people can now discuss topics on platforms like Twitter.
2. The FDA has not provided clear guidance for pharmaceutical companies on social media use, but holds meetings to get public input on developing guidelines.
3. Some key challenges for healthcare companies engaging on social media include adverse event reporting and maintaining fair balance in discussions.
Pharmaceutical companies have often been uncertain about how to meet their regulatory obligations while engaging in the new social media forums favored by consumers and physicians alike. FDA has released its first guidance addressing this topic since its 2009 hearings on the subject. The guidance addresses how sponsors can fulfill their requirement to file all material at the time of first use (the 2253 requirement) while engaging in real-time conversations.
This presentation examines key aspects of the guidance including:
* Status of user-generated content (UGC) and companies' reporting obligation for UGC
* Ability to meet 2253 filing requirements in the context of real-time conversations
* Implications of the guidance for filing online promotional materials other than social media
* Some open questions left unanswered by the guidance
Social Media Considerations In Pharmacovigilance Visiongain 20110317 (Sande...Sandeep Bhat
The document discusses considerations for using social media in pharmacovigilance. It defines social media and outlines key differences and similarities between social media and pharmacovigilance. Technology professionals view social media as a data deluge that requires semantic enablement and metadata management, while media professionals see areas of influence and influence channels. Gaining support requires shepherds, stewards, leaders, connectors, and controllers. The document also discusses people, processes, tools, accuracy, feedback to the public, news articles on the topic, and provides sample social media guidelines.
This is the annotated and expanded version of WEGO Health’s presentation at the FDA’s Public Hearing and the Health Activist Social Media Survey results with graphs and explanations.
WEGO Health FDA Social Media Presentation, Questions 1-3WEGO Health
Health activists see themselves as opinion leaders through their social media activities, creating content for large audiences to discuss health issues. They view social media as important for health communication. While they feel companies should participate and provide accurate information, companies must also address misinformation and follow regulations. Health activists want regulations that allow for open conversations and do not prevent company participation, and they feel the FDA should tailor regulations to fit social media realities.
Safety and Social Media Dia webinar 12 sep2013 Michael Ibara
This is a webinar version of a talk I originally gave at a DIA event in Wash DC. I've used different examples from my original talk but the theme is the same.
Companies can leverage social media to drive business and compete effectively in the new era of health care. But what do you need to know before jumping in or expanding your efforts? What considerations do medical technology marketing professionals need to take into account when implementing a strategic social-media plan?
Part one of our five-part series outlines how medical technology professionals can use social media in a regulated environment. Even more importantly, it gives readers the supporting evidence needed to recommend specific social-media strategies to management and internal legal and regulatory teams.
CMI Compas One Click Rule POV June 2015Cory LeBihan
The document discusses a proposed bill called the "One Click Rule" that would allow pharmaceutical companies more freedom to use social media for marketing. It would allow inclusion of important safety information (ISI) through a link rather than requiring it to be displayed in full within social media posts. This would address current FDA regulations that make it difficult for pharma brands to mention medical conditions and drugs in short social media posts due to ISI length. The bill could significantly expand pharma's ability to promote drugs on large social networks if passed and the FDA revises guidelines accordingly. Analysts believe it would give brands more flexibility to engage online audiences about medical products and conditions.
Examine why hospitals may want to consider a more comprehensive plan in using social media before hopping on Facebook. If you are already on Facebook examine the issues and re-strategize.
Every business needs to be on social media these days. However, social media can be legally risky if done wrong! Learn five top tips to keep your business from getting sued while using social media for marketing.
The document discusses the growing use of social networks in the healthcare industry for sharing health information. It outlines four types of healthcare social networks: those founded by individuals to discuss specific diseases, those run by nonprofit organizations, those created by startup companies, and those started by established healthcare/pharmaceutical corporations. The challenges of corporate involvement are addressed, such as managing off-label promotion and adverse event reporting. Transparency, privacy, and not competing with existing networks are recommended.
This document summarizes a research study analyzing the impact of social media on employment. The study surveyed 200 employees and student athletes about their social media use, privacy settings, and views on employers monitoring accounts. The introduction discusses how employers are increasingly viewing social media to make hiring decisions. The literature review summarizes several sources discussing both positive and negative consequences of social media use in the workplace. The justification section argues that as social media becomes more integrated into personal and professional life, users must be aware that online content can affect future employment opportunities.
The document discusses the evolving role of social media and web-based adverse event reporting in pharmacovigilance. It argues that current drug safety regulations were developed when data was scarce, but we now live in a world of abundant safety data due to digitization of healthcare information. New business models for drug safety are possible through dramatically lower costs of collecting and reporting safety data. However, our old regulatory concepts clash with this new environment. The document suggests designating social media information as a public good and formulating new rules and report types to better govern drug safety in this digital world.
The document discusses regulation of the internet and social media by the FDA. It argues that the current regulatory approach has become obsolete given changes in communication technologies. While the FDA aims to protect public health, its actions have disrespected free speech and shown a lack of understanding of new media. The document recommends that the FDA take time to understand how consumers actually use the internet for health information before making evidence-based policy decisions. It also suggests partnering with technology companies and incorporating advisory committees to develop guidance better suited to the fast-paced social media environment.
The document summarizes feedback from stakeholders on AstraZeneca's submission to the FDA regarding social media engagement in the pharmaceutical industry.
Key discussion points included that social media is important for advancing public health, and pharmaceutical companies have a responsibility to engage more in social media. Stakeholders provided feedback on the FDA's role as regulator, noting social media requires a tailored approach, and companies can help address misinformation online. They also covered pharmaceutical companies' role, emphasizing the need for ongoing dialogue and mutual agreement with patients/caregivers.
The thoughts of patients, health advocates, former government officials, bloggers and others who participated in a roundtable discussion that AstraZeneca convened in 2010.
This document summarizes feedback from stakeholders on AstraZeneca's submission to the FDA regarding social media engagement in the pharmaceutical industry. Key discussion points included that social media is important for advancing public health and that pharmaceutical companies have a responsibility to engage more in social media. Regarding the FDA, stakeholders felt they should recognize social media as a unique forum requiring tailored regulation and work more closely with industry. For pharmaceutical companies, stakeholders emphasized the importance of ongoing dialogue with patients/caregivers and ensuring mutual agreement and benefit from social media engagement.
In late 2011, the FDA released a document addressing how the pharmaceutical industry can and should respond to requests about off-label drug usage. This POV provides more information about the guidance document, highlights the key issues, and offers use cases to consider in the digital realm.
Social Media Guidelines and Safeguards for the Phamaceutical Industry: What Y...Stacy Lukasavitz Steele
This is a POV I wrote in June 2010 advising pharmaceutical companies on what they should do in the social media space until the FDA issues its official guidelines. It will soon be updated.
Healthcare marketers understand the value of social media, but may not feel prepared to participate in such a tightly regulated space. How can you join the conversation while protecting your organization? With these five documents, you can safely enter the world of social media while reducing your liability and maintaining a consistent company message.
Visit us at www.GreyMatterMarketing.com
Point of view of the recently released draft guidance for industry for pharma and social media by Navicor - an Oncology focused marketing and communications company.
1. Social media is changing how health information is shared, as people can now discuss topics on platforms like Twitter.
2. The FDA has not provided clear guidance for pharmaceutical companies on social media use, but holds meetings to get public input on developing guidelines.
3. Some key challenges for healthcare companies engaging on social media include adverse event reporting and maintaining fair balance in discussions.
Pharmaceutical companies have often been uncertain about how to meet their regulatory obligations while engaging in the new social media forums favored by consumers and physicians alike. FDA has released its first guidance addressing this topic since its 2009 hearings on the subject. The guidance addresses how sponsors can fulfill their requirement to file all material at the time of first use (the 2253 requirement) while engaging in real-time conversations.
This presentation examines key aspects of the guidance including:
* Status of user-generated content (UGC) and companies' reporting obligation for UGC
* Ability to meet 2253 filing requirements in the context of real-time conversations
* Implications of the guidance for filing online promotional materials other than social media
* Some open questions left unanswered by the guidance
Social Media Considerations In Pharmacovigilance Visiongain 20110317 (Sande...Sandeep Bhat
The document discusses considerations for using social media in pharmacovigilance. It defines social media and outlines key differences and similarities between social media and pharmacovigilance. Technology professionals view social media as a data deluge that requires semantic enablement and metadata management, while media professionals see areas of influence and influence channels. Gaining support requires shepherds, stewards, leaders, connectors, and controllers. The document also discusses people, processes, tools, accuracy, feedback to the public, news articles on the topic, and provides sample social media guidelines.
This is the annotated and expanded version of WEGO Health’s presentation at the FDA’s Public Hearing and the Health Activist Social Media Survey results with graphs and explanations.
WEGO Health FDA Social Media Presentation, Questions 1-3WEGO Health
Health activists see themselves as opinion leaders through their social media activities, creating content for large audiences to discuss health issues. They view social media as important for health communication. While they feel companies should participate and provide accurate information, companies must also address misinformation and follow regulations. Health activists want regulations that allow for open conversations and do not prevent company participation, and they feel the FDA should tailor regulations to fit social media realities.
Safety and Social Media Dia webinar 12 sep2013 Michael Ibara
This is a webinar version of a talk I originally gave at a DIA event in Wash DC. I've used different examples from my original talk but the theme is the same.
Companies can leverage social media to drive business and compete effectively in the new era of health care. But what do you need to know before jumping in or expanding your efforts? What considerations do medical technology marketing professionals need to take into account when implementing a strategic social-media plan?
Part one of our five-part series outlines how medical technology professionals can use social media in a regulated environment. Even more importantly, it gives readers the supporting evidence needed to recommend specific social-media strategies to management and internal legal and regulatory teams.
CMI Compas One Click Rule POV June 2015Cory LeBihan
The document discusses a proposed bill called the "One Click Rule" that would allow pharmaceutical companies more freedom to use social media for marketing. It would allow inclusion of important safety information (ISI) through a link rather than requiring it to be displayed in full within social media posts. This would address current FDA regulations that make it difficult for pharma brands to mention medical conditions and drugs in short social media posts due to ISI length. The bill could significantly expand pharma's ability to promote drugs on large social networks if passed and the FDA revises guidelines accordingly. Analysts believe it would give brands more flexibility to engage online audiences about medical products and conditions.
Potential of One Click Rule to Change Pharma Marketing: How a Bill in Congres...CMI_Compas
The document discusses a proposed bill called the "One Click Rule" that would allow pharmaceutical companies more freedom to use social media for marketing. It would allow inclusion of important safety information (ISI) through a link rather than requiring it to be displayed in full within social media posts. This would address current FDA regulations that make it difficult for pharma brands to mention medical conditions and drugs in short social media posts due to ISI length. The bill could significantly expand pharma's ability to promote drugs on large social networks if passed and the FDA revises guidelines accordingly. Analysts believe it would give brands more flexibility to engage online audiences about medical products and conditions.
The document discusses using social media marketing as part of a multichannel marketing strategy for pharmaceutical companies. It outlines both the opportunities and challenges of using social media in the pharmaceutical space, providing examples of companies like Johnson & Johnson and Pfizer that have successfully leveraged social media. The document argues that while social media presents regulatory challenges, it also provides opportunities to engage customers and communities in meaningful two-way conversations if done properly.
Healthy Voices - Session Eight - Representing yourself and your organisationhealthyvoices
Session eight of an eight session training course designed to develop participant skills in communicating online. This session covers ethical and branding considerations when publishing online.
The document summarizes an introduction to the FDA Social Media Hearing (FDASM). It provides background on the purpose of the hearing, which is to get public input on how expanded web technologies can be used to promote medical products to healthcare professionals and consumers in a truthful manner, and on internet adverse event reporting. The main questions to be addressed at the hearing are about accountability, regulatory requirements for social media promotion, corrective information on third party sites, appropriate use of links, and adverse event reporting. Highlights from a previous forum on related issues are also summarized.
Similar to Overcoming Pharma’s Social Media Challenges (20)
SATTA MATKA SATTA FAST RESULT KALYAN TOP MATKA RESULT KALYAN SATTA MATKA FAST RESULT MILAN RATAN RAJDHANI MAIN BAZAR MATKA FAST TIPS RESULT MATKA CHART JODI CHART PANEL CHART FREE FIX GAME SATTAMATKA ! MATKA MOBI SATTA 143 spboss.in TOP NO1 RESULT FULL RATE MATKA ONLINE GAME PLAY BY APP SPBOSS
3 Simple Steps To Buy Verified Payoneer Account In 2024SEOSMMEARTH
Buy Verified Payoneer Account: Quick and Secure Way to Receive Payments
Buy Verified Payoneer Account With 100% secure documents, [ USA, UK, CA ]. Are you looking for a reliable and safe way to receive payments online? Then you need buy verified Payoneer account ! Payoneer is a global payment platform that allows businesses and individuals to send and receive money in over 200 countries.
If You Want To More Information just Contact Now:
Skype: SEOSMMEARTH
Telegram: @seosmmearth
Gmail: seosmmearth@gmail.com
Top mailing list providers in the USA.pptxJeremyPeirce1
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
[To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
This PowerPoint compilation offers a comprehensive overview of 20 leading innovation management frameworks and methodologies, selected for their broad applicability across various industries and organizational contexts. These frameworks are valuable resources for a wide range of users, including business professionals, educators, and consultants.
Each framework is presented with visually engaging diagrams and templates, ensuring the content is both informative and appealing. While this compilation is thorough, please note that the slides are intended as supplementary resources and may not be sufficient for standalone instructional purposes.
This compilation is ideal for anyone looking to enhance their understanding of innovation management and drive meaningful change within their organization. Whether you aim to improve product development processes, enhance customer experiences, or drive digital transformation, these frameworks offer valuable insights and tools to help you achieve your goals.
INCLUDED FRAMEWORKS/MODELS:
1. Stanford’s Design Thinking
2. IDEO’s Human-Centered Design
3. Strategyzer’s Business Model Innovation
4. Lean Startup Methodology
5. Agile Innovation Framework
6. Doblin’s Ten Types of Innovation
7. McKinsey’s Three Horizons of Growth
8. Customer Journey Map
9. Christensen’s Disruptive Innovation Theory
10. Blue Ocean Strategy
11. Strategyn’s Jobs-To-Be-Done (JTBD) Framework with Job Map
12. Design Sprint Framework
13. The Double Diamond
14. Lean Six Sigma DMAIC
15. TRIZ Problem-Solving Framework
16. Edward de Bono’s Six Thinking Hats
17. Stage-Gate Model
18. Toyota’s Six Steps of Kaizen
19. Microsoft’s Digital Transformation Framework
20. Design for Six Sigma (DFSS)
To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations
[To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
This presentation is a curated compilation of PowerPoint diagrams and templates designed to illustrate 20 different digital transformation frameworks and models. These frameworks are based on recent industry trends and best practices, ensuring that the content remains relevant and up-to-date.
Key highlights include Microsoft's Digital Transformation Framework, which focuses on driving innovation and efficiency, and McKinsey's Ten Guiding Principles, which provide strategic insights for successful digital transformation. Additionally, Forrester's framework emphasizes enhancing customer experiences and modernizing IT infrastructure, while IDC's MaturityScape helps assess and develop organizational digital maturity. MIT's framework explores cutting-edge strategies for achieving digital success.
These materials are perfect for enhancing your business or classroom presentations, offering visual aids to supplement your insights. Please note that while comprehensive, these slides are intended as supplementary resources and may not be complete for standalone instructional purposes.
Frameworks/Models included:
Microsoft’s Digital Transformation Framework
McKinsey’s Ten Guiding Principles of Digital Transformation
Forrester’s Digital Transformation Framework
IDC’s Digital Transformation MaturityScape
MIT’s Digital Transformation Framework
Gartner’s Digital Transformation Framework
Accenture’s Digital Strategy & Enterprise Frameworks
Deloitte’s Digital Industrial Transformation Framework
Capgemini’s Digital Transformation Framework
PwC’s Digital Transformation Framework
Cisco’s Digital Transformation Framework
Cognizant’s Digital Transformation Framework
DXC Technology’s Digital Transformation Framework
The BCG Strategy Palette
McKinsey’s Digital Transformation Framework
Digital Transformation Compass
Four Levels of Digital Maturity
Design Thinking Framework
Business Model Canvas
Customer Journey Map
The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...APCO
The Radar reflects input from APCO’s teams located around the world. It distils a host of interconnected events and trends into insights to inform operational and strategic decisions. Issues covered in this edition include:
Call8328958814 satta matka Kalyan result satta guessing➑➌➋➑➒➎➑➑➊➍
Satta Matka Kalyan Main Mumbai Fastest Results
Satta Matka ❋ Sattamatka ❋ New Mumbai Ratan Satta Matka ❋ Fast Matka ❋ Milan Market ❋ Kalyan Matka Results ❋ Satta Game ❋ Matka Game ❋ Satta Matka ❋ Kalyan Satta Matka ❋ Mumbai Main ❋ Online Matka Results ❋ Satta Matka Tips ❋ Milan Chart ❋ Satta Matka Boss❋ New Star Day ❋ Satta King ❋ Live Satta Matka Results ❋ Satta Matka Company ❋ Indian Matka ❋ Satta Matka 143❋ Kalyan Night Matka..
How MJ Global Leads the Packaging Industry.pdfMJ Global
MJ Global's success in staying ahead of the curve in the packaging industry is a testament to its dedication to innovation, sustainability, and customer-centricity. By embracing technological advancements, leading in eco-friendly solutions, collaborating with industry leaders, and adapting to evolving consumer preferences, MJ Global continues to set new standards in the packaging sector.
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
Digital Marketing with a Focus on Sustainabilitysssourabhsharma
Digital Marketing best practices including influencer marketing, content creators, and omnichannel marketing for Sustainable Brands at the Sustainable Cosmetics Summit 2024 in New York
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...my Pandit
Explore the fascinating world of the Gemini Zodiac Sign. Discover the unique personality traits, key dates, and horoscope insights of Gemini individuals. Learn how their sociable, communicative nature and boundless curiosity make them the dynamic explorers of the zodiac. Dive into the duality of the Gemini sign and understand their intellectual and adventurous spirit.
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Final ank Satta Matka Dpbos Final ank Satta Matta Matka 143 Kalyan Matka Guessing Final Matka Final ank Today Matka 420 Satta Batta Satta 143 Kalyan Chart Main Bazar Chart vip Matka Guessing Dpboss 143 Guessing Kalyan night
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...Neil Horowitz
On episode 272 of the Digital and Social Media Sports Podcast, Neil chatted with Brian Fitzsimmons, Director of Licensing and Business Development for Barstool Sports.
What follows is a collection of snippets from the podcast. To hear the full interview and more, check out the podcast on all podcast platforms and at www.dsmsports.net
How to Implement a Real Estate CRM SoftwareSalesTown
To implement a CRM for real estate, set clear goals, choose a CRM with key real estate features, and customize it to your needs. Migrate your data, train your team, and use automation to save time. Monitor performance, ensure data security, and use the CRM to enhance marketing. Regularly check its effectiveness to improve your business.
1. Thank
you
for
invi.ng
me
speak
at
the
Roche
Digital
Academy!
Unfortunately,
I
will
have
to
speak
rapidly
in
English
to
get
through
all
my
slides
in
the
alloAed
.me,
but
I
am
sure
you
will
get
a
copy
of
my
slides
–
including
my
notes
–
to
read
at
your
leisure
aDerward.
2. I
this
presenta.on,
I
will
show
you
some
pharma
social
media
“milestones”
or
“firsts”
that
have
paved
the
way
for
others
to
follow.
I
will
iden.fy
the
“Pioneers”
who
have
helped
the
industry
navigate
through
“uncharted”
territory
lacking
regulatory
guidance.
I
will
also
show
you
some
“mistakes”
made
by
both
leaders
and
followers.
Only
those
who
learn
from
thee
mistakes
of
their
compe.tors
will
move
forward.
Those
who
learn
from
their
OWN
mistakes
will
move
forward
fastest!
Finally,
I
will
present
some
ideas
for
“best
prac.ces”
and
“guiding
principles”
that
may
help
you
avoid
regulatory
ac.ons.
3. The
dic.onary
defines
"aficionado"
as
a
“person
who
is
very
knowledgeable
and
enthusias.c
about
an
ac.vity,
subject,
or
pas.me.”
I
have
been
around
for
a
quite
some
.me
and
have
first-‐hand
experience
with
government
regulatory
and
voluntary
industry
codes
of
prac.ce.
Studying
digital
pharma
has
been
my
“pas.me”
for
many
years.
But
I
don’t
just
study
digital
pharma,
I
document
and
try
to
INFLUENCE
it,
as
you
will
see
in
the
following
slides.
4. FDA’s
famous
14
leAers
alerted
pharma
to
the
fact
that
the
agency
is
now
looking
carefully
at
how
the
industry
promotes
its
products
via
the
Internet.
I
pushed
this
issue
in
December
2006
when
I
blogged
that
“FDA
should
be
taking
a
closer
look
at
drug
promo.on
via
the
Internet.”
And
the
.ming
of
my
2009
April
Fools’
joke
was
perfect
–
many
pharma
people
were
primed
to
believe
the
FDA
actually
came
out
with
digital
guidance
and
several
were
angry
at
me
for
playing
such
a
cruel
joke!
5. The
14
leAers
took
aim
squarely
at
the
so-‐called
“one-‐click
rule”
which
was
not
a
rule
at
all
–
it
was
just
what
pharma
people
wanted
to
believe
and
were
lead
to
believe
by
FDA’s
inac.on
prior
to
the
14
leAers.
In
fact,
I
warned
the
industry
about
the
invalidity
of
this
“rule”
or
“received
wisdom”
as
far
back
as
November,
2006,
when
I
debated
it
at
an
industry
conference.
Alas,
only
someone
outside
the
industry
could
see
that
the
Emperor
had
no
clothes!
6. I’d
like
to
believe
that
my
call
for
public
hearings
back
in
April
2009,
mo.vated
the
FDA
to
act.
Unfortunately,
however,
the
hearings
were
has.ly
organized
and
as
a
result,
they
did
not
include
ALL
stakeholders
as
I
urged.
Consumer
advocates
were
missing
and
agencies
and
industry
service
providers
dominated
the
speaker
roster.
Rela.ve
to
the
1996
hearing,
few
pharma
companies
made
presenta.ons
at
the
2009
hearing.
This
shirt
appeared
in
my
presenta.on
to
the
FDA
at
the
November
hearings!
It
was
my
way
of
predic.ng
the
outcome.
7. Congress
put
some
language
in
in
recent
legisla.on
that
requires
the
FDA
to
issue
social
media
guidance
by
July
2014.
Does
that
mean
the
FDA
will
deliver?
If
not,
it
wouldn't
be
the
first
.me
that
a
government
agency
missed
deadlines
imposed
by
Congress.
I
call
this
FDA's
"Social
Media
Guidance
Cliff.”
FDA
Safety
and
Innova.on
Act
(FDASIA)-‐TRACK
must
include
the
deliverables
with
statutory
dates,
as
well
as
other
tasks
required
to
implement
the
law.
To
date,
no
“other
tasks”
for
SM
guidance
have
been
entered
in
the
database.
Why
the
delay?
Perhaps
the
industry
wants
legally
binding
regula.ons,
not
guidance.
Pfizer,
for
example,
contends
that
FDA’s
proposed
social
media
guidance
“raises
First
Amendment
concerns.”
Guidance,
said
Pfizer,
is
too
vague
and
engenders
“extensive
[First
Amendment]
li.ga.on.”
8. Over
the
2011
Christmas
holidays,
while
most
of
us
were
s.ll
on
vaca.on,
the
FDA
quietly
issued
without
fanfare
"Guidance
for
Industry
Responding
to
Unsolicited
Requests
for
Off-‐Label
Informa.on
About
Prescrip.on
Drugs
and
Medical
Devices."
Sec.on
VI.
of
this
guidance
addresses
responding
to
unsolicited
requests
on
public
forums
such
as
the
Internet.
While
this
may
not
be
the
"social
media"
guidance
many
people
were
expec.ng,
it
does
include
guidelines
for
responding
to
unsolicited
requests
for
off-‐label
informa.on
encountered
through
"emerging
electronic
media.”
The
primary
take-‐away
is
that
such
requests
NOT
be
handled
by
sales
or
marke.ng
people
and
that
responses
should
be
via
private
channels
not
via
open
forums
such
as
on
Youtube,
blogs,
and
TwiAer.
9. As
soon
as
the
FDA
issued
the
public
no.ce
about
the
hearings
and
posted
19
ques.ons
it
was
seeking
to
answer,
I
hosted
a
survey
that
asked
my
readers
to
respond
to
those
same
19
ques.ons.
FDA
asked
“Open-‐Ended”
ques.ons.
My
survey
asked
respondents
to
vote
on
specific
op.ons
as
well
as
including
comment
boxes.
I
submiAed
the
complete
survey
results
to
the
FDA
docket
and
summarized
the
results
in
my
presenta.ons
at
the
hearing.
The
following
slides
also
summarize
some
results
from
that
survey
as
well
as
comments
submiAed
to
the
docket
by
major
pharma
companies.
10. FDA
asked
“Open-‐Ended”
ques.ons.
My
survey
asked
respondents
to
vote
on
specific
op.ons
as
well
as
including
open-‐comment
boxes.
Regarding
accountability,
the
survey
wanted
to
compare
situa.ons
where
pharma
paid
for
content,
provided
grants
for
independent
content,
or
sponsored
branded
ads
that
targeted
specific
3rd-‐party
content.
11. Another
survey
I
hosted
asked
slightly
different
ques.ons
in
an
aAempt
to
define
some
“best
prac.ces”
regarding
disclosures
and
accountability.
One
“best
prac.ce”
that
I’d
like
to
see
more
companies
prac.ce
is
a
Public
Social
Media
Policy
that
includes
a
no.ce
of
its
transparency/
disclosure
and
other
policies
rela.ng
to
social
media.
About
two-‐thirds
of
survey
respondents
agree
with
me!
I
know
of
only
one
company
that
has
a
public
social
media
policy.
That
company
is
Roche.
12. Comments
submiAed
to
the
FDA
docket
by
the
drug
industry
allow
us
to
learn
more
about
what
the
industry
considers
to
be
best
social
media
prac.ces
and
where
it
believes
the
regulatory
boundaries
are.
Not
all
pharma
companies,
however,
agree
on
defini.ons
or
where
to
draw
the
boundaries.
13. Back
to
my
survey.
How
pharma
corrects
or
allows
misinforma.on
to
be
posted
on
social
media
sites
it
controls
is
an
important
part
of
its
social
media
policy
that
should
be
revealed
to
visitors
of
such
sites.
Nearly
a
majority
of
pharma
respondents
would
not
like
to
see
FDA
mandate
that
they
correct
misinforma.on
about
products
on
3rd-‐party
sites,
although
about
one-‐fiDh
think
misinforma.on
of
real
and
imminent
danger
to
the
public
health
(to
be
determined
by
company)
should
be
corrected.
14. One
important
3rd-‐party
site
where
misinforma.on
about
drugs
may
be
found
is
Wikipedia.
“If
you
want
your
customers
to
access
informa.on
about
your
products
from
the
quality
perspec.ve
and
in
the
simplest
way,
you
have
to
deal
with
using
Wikipedia,”
said
Dr.
Bertalan
Meskó
(@Berci).
Berci,
however,
did
not
mean
that
pharma
companies
should
secretly
and
selec.vely
alter
informa.on
as
in
this
example:
In
July
of
2007,
employees
of
AbboA
Laboratories
altered
entries
to
Wikipedia
to
eliminate
informa.on
about
a
Mayo
Clinic
study
that
revealed
that
pa.ents
taking
the
arthri.s
drug
Humira
faced
triple
the
risk
of
developing
certain
kinds
of
cancers
and
twice
the
risk
of
developing
serious
infec.ons.
I
hosted
another
survey
asking
respondents
under
what
circumstances
should
pharma
edit
drug
ar.cles
on
Wikipedia.
Based
on
this.
The
best
prac.ce
is
to
appoint
an
“official”
Wikipedia
editor
as
recommended
by
Berci
and
ensure
that
editors
reveal
.es
to
companies.
Although
a
substan.al
minority
of
respondents
feel
that
FDA
should
regulate
pharma
edits
to
Wikipedia
drug
ar.cles,
in
comments
submiAed
to
the
FDA
docket,
PhRMA
suggested
that
manufacturers
would
welcome
correc.ng
misinforma.on
about
their
products
posted
to
3rd-‐party
sites
such
as
14
15. According
to
my
survey,
the
vast
majority
–
83%
–
of
pharma
respondents
think
it
is
impossible
to
adequately
handle
AEs
from
social
media
sources.
“It's
remarkable
how
very
liAle
we
see
that
meets
the
criteria
of
an
adverse
event,”
said
one
pharma
respondent.
The
criteria
referred
to
are
these:
an
iden.fiable
pa.ent,
a
specific
medica.on,
an
iden.fiable
reporter
and
a
reac.on.
16. The
“iden.fiable
reporter”
is
the
most
difficult
bit
of
“required”
informa.on
to
obtain.
“Many
people
use
the
Internet
to
share
informa.on
and
remain
anonymous
when
doing
so,
even
if
an
email
address
or
other
personal
(excluding
a
name)
is
provided,”
noted
PhRMA
in
its
comments
to
the
FDA.
“Unless
people
opt-‐in
to
say
they
want
their
informa.on
to
be
shared
with
pharmaceu.cal
(or
other)
companies,
these
companies
should
not
pursue
contac.ng
a
person
if
an
AE
is
reported.
While
not
everyone
understands
that
AEs
can
be
reported
directly
to
the
FDA
or
a
company,
there
needs
to
be
more
emphasis
to
consumers
about
how
they
should/can
report
AEs
so
that
companies
are
not
liable
for
what
they
"happen"
to
find
online.”
In
light
of
all
the
emphasis
US
pharma
companies
place
on
“iden.fiable
reporter,”
it
is
interes.ng
that
ABPI
(UK)
advised
its
members
that
“AEs
should
be
collected
and
documented,
regardless
of
seriousness
of
event
and
whether
or
not
there
is
an
iden.fiable
reporter”
(see
SLIDE
#
X).
17. Pharma
companies
had
some
sugges.ons
for
how
FDA
could
help
the
industry
deal
with
online
adverse
event
reports.
18. Meanwhile,
some
companies
are
sexng
the
“Gold
Standard”
for
managing
online
adverse
event
reports
and
deploying
the
necessary
resources
to
make
it
possible.
19. The
Associa.on
of
the
Bri.sh
Pharmaceu.cal
Industry
has
also
come
out
with
specific
guidelines
for
managing
adverse
events
on
pharma
owned
or
sponsored
Web
sites.
Interes.ngly,
the
guidelines
ignore
the
“iden.fiable
reporter”
condi.on
required
by
the
FDA
for
an
AE
to
be
“reportable.”
The
Brits
have
also
issued
some
guidance
for
using
TwiAer
to
communicate
with
physicians,
making
correc.ons
to
Wikipedia
–
an
issue
discussed
in
a
previous
slide
–
and
appropriate
use
of
metadata.
You
can
find
details
by
following
the
links
given.
20. Despite
the
lack
of
FDA
guidance,
pharmaceu.cal
marketers
have
come
a
long
way
in
integra.ng
social
media
into
their
overall
marke.ng
strategy.
These
are
data
from
the
Social
Media
Readiness
survey
tool
I
have
been
running
since
December,
2007.
Over
300
marketers
working
for
drug
or
device
companies
have
taken
the
survey.
The
survey
asks
ques.ons
to
evaluate
readiness
in
three
categories:
regulatory
(e.g.,
aversion
of
risk),
culture
(e.g.,
sensi.vity
to
cri.cism),
and
personal
experience.
Scores
are
calculated.
This
compares
scores
prior
to
July,
2009,
with
scores
aDerward.
Not
every
pharma
company,
however,
is
at
the
same
point
in
the
adop.on
curve.
Some
are
more
willing
to
take
"risks,"
some
are
more
savvy
about
applicable
FDA
regula.ons,
and
some
are
more
knowledgeable
about
social
media
in
general.
Let’s
see
how
Roche
did.
20
21. These
results,
of
course,
are
based
on
a
very
small
number
of
responses.
It
seems,
however,
that
Roche
employees
feel
that
the
company
is
savvy
regarding
the
regulatory
issues
rela.ng
to
social
media
but
lacks
the
type
of
culture
required
to
be
comfortable
with
making
social
media
mistakes.
If
you
have
not
taken
the
survey,
please
do.
I
can
report
back
updated
results
aDerward.
21
22. Let’s
look
at
more
detail
regarding
how
pharma
employees
rate
their
companies’
readiness
to
deal
with
social
media
readiness
issues.
You
can
see
that
in
the
early
period
prior
to
July
2009,
the
majority
of
respondents
thought
their
companies
had
a
“very
cau.ous”
regulatory
climate
with
only
24%
saying
the
climate
was
“very
aggressive.”
Theses
days,
it
seems
from
these
results,
pharma
companies
are
seen
as
much
less
cau.ous
and
more
aggressive.
I
guess
that
is
due
to
the
lack
of
significant
FDA
“warning”
leAers
being
sent
that
involve
social
media.
In
other
words,
the
“received
wisdom”
is
that
pharma
companies
are
nego.a.ng
the
social
media
regulatory
challenges
without
specific
guidance
from
the
FDA.
Be
careful
though!
The
FDA
hammer
may
fall
again
just
as
it
did
the
day
aDer
April
Fools’
Day
in
2009.
22
23. While
pharma
may
be
gexng
more
comfortable
engaging
in
social
media
without
FDA
guidance,
there
has
been
some
retrenchment
in
adop.ng
social
media
for
marke.ng.
For
example,
there
are
fewer
pharma
Facebook
pages
today
than
there
were
prior
to
August
15,
2011,
when
Facebook
changed
its
policy
on
comments.
ADer
the
change,
which
did
not
allow
pharma
companies
to
turn
off
comments
to
their
Facebook
pages,
many
companies
just
shut
down
their
pages.
"This
new
policy
will
alter
our
ability
to
consider
the
appropriateness
of
comments
before
they
are
posted
which
is
important
to
us
as
a
company
in
a
highly
regulated
industry,”
said
McNeil
Pediatrics
when
it
shut
down
its
ADHD
Moms
page.
24. An
example
of
this
was
the
shutdown
of
the
Psoriasis
Facebook
page
by
Janssen
Pharmaceu.cals.
This
page
–
launched
in
October,
2010
–
was
the
first
pharma
Facebook
page
that
published
comments
BEFORE
reviewing
but
reserved
the
right
to
delete
them
aDerward.
Janssen
cited
its
inability
to
moderate
posts
made
to
the
Psoriasis
360
wall,
one-‐third
of
which
"men.on[ed]
a
specific
drug
by
name,
or
talk[ed]
about
the
efficacy
of
a
par.cular
treatment
is
(or
its
side
effects)."
In
such
cases,
Janssen
had
to
ask
for
the
post
to
be
removed
or
to
"pull"
it.
Perhaps
this
decision
represents
a
lack
of
commitment
aDer
Alex
Butler,
former
Janssen
Digital
Strategy
and
Social
Media
Manager,
leD
the
company.
Alex
was
the
person
responsible
for
Psoriasis
360.
For
his
efforts,
I
awarded
him
the
first
ever
Pharmaguy
Social
Media
Pioneer
award.
Another
example
was
the
shutdown
of
the
ADHD
Moms
Facebook
page
by
McNeil
Pediatrics.
This
was
the
first
pharma
Facebook
page
–
launched
in
June,
2008.
"This
new
policy
will
alter
our
ability
to
consider
the
appropriateness
of
comments
before
they
are
posted
which
is
important
to
us
as
a
company
in
a
highly
regulated
industry,”
said
McNeil.
25. There
were
examples
of
pharma-‐owned
or
sponsored
open
discussion
boards
even
before
Facebook
became
popular.
GSK’s
Ques.onEverything,
which
was
launched
in
April,
2006,
is
an
example.
It
allowed
comments
from
consumers
and
posted
them
aDer
review
(“pre-‐modera.on”).
This
site
is
no
longer
available.
Pre-‐modera.on
–
where
possible
–
may
be
the
best
prac.ce
for
pharma
social
media
sites,
including
YouTube.
However,
these
days,
very
few
pharma
companies
allow
any
comments
at
all,
which
is
a
shame
because
that
is
the
best
way
to
build
community
and
aAract
more
viewers
26. Of
course,
there
is
good
reason
why
pharma
companies
fear
comments
on
Facebook
as
this
case
demonstrates.
However,
this
could
have
been
prevented:
• Problem
#1:
No
one
at
S-‐A
was
monitoring
this
site
or
seemed
to
be
responsible
for
it.
• Problem
#2:
There
was
no
policy
in
place
for
what
cons.tutes
acceptable
comments
and
how
comments
would
be
moderated
or
deleted.
• Problem
#3:
There
was
no
social
media
“crisis
management
plan”
other
than
“remove
all
comments!”
27. Sanofi
learned
from
its
mistakes
and
even
spoke
about
them
in
a
public
forum;
i.e.,
my
Pharma
Marke.ng
Talk
show
.tled:
“What
Sanofi-‐Aven.s
Learned
from
Its
FaceBook
Experience
&
What
the
Experts
Recommend
It
Do
Now.”
In
that
show
I
interviewed
Dennis
Urbaniak,
VP
U.S.
Diabetes.
Listen
to
the
podcast:
hAp://bit.ly/PMT098
The
Sanofi
US
Diabetes
team
won
the
third
(2012)
Pharmagy
Social
Media
Pioneer
Award.
28. Even
the
biggest
pharma
company
in
the
world
can
be
humbled
by
Facebook
backlash.
In
this
case,
it
was
Pfizer
and
the
product
is
not
regulated
by
the
FDA.
Nevertheless,
it
illustrates
how
important
it
is
to
pay
aAen.on
to
what’s
going
on
in
the
social
media
spaces
that
you
own
and
to
have
a
“crisis
plan”
in
place.
The
issue
was
this:
Pfizer
selec.vely
deleted
“nega.ve”
comments
in
an
aAempt
to
control
the
discussion.
What’s
the
lesson?
You
are
NOT
in
control
of
the
discussion
on
social
media.
This
is
pharma’s
major
social
media
conundrum:
(1) pharma
marketers
are
used
to
controlling
the
discussion
(or
not
having
a
discussion
at
all),
and
(2) pharma
marketers
are
legally
responsible
for
the
content
of
the
discussions
on
sites
they
own.
29. Although
Pfizer
got
into
trouble
with
comments
on
Facebook,
it
did
not
shrink
from
allowing
comments
on
other
social
media
sites
like
its
“Get
Old”
community.
On
June
18,
2012,
Pfizer
launched
"Get
Old,"
a
mul.-‐year
ini.a.ve
supported
by
nearly
a
dozen
advocacy
organiza.ons.
Registered
users
can
post
links,
videos,
photos,
or
stories
(including
comments
up
to
1000
characters)
to
the
site.
You
can
even
submit
comments
to
other
posts
and
"Like,"
tweet,
or
email
comments.
Every
comment
submiAed
is
reviewed
before
being
uploaded
-‐
a
process
that
is
completed
within
48
hours.
Pfizer
says
it
has
a
social
media
“Playbook,”
according
to
Ray
Kerins,
Pfizer’s
former
Vice
President
of
Worldwide
Communica.ons.
“While
I
don't
want
to
say
it's
proprietary,”
said
Kerins,
“I
also
don't
want
to
make
too
big
of
a
deal
about
it
because
we
call
it
common
sense.”
30. In
the
U.S.,
of
course,
direct-‐to-‐consumer
branded
drug
adver.sing
is
permissible,
but
is
it
always
necessary?
I
cri.cized
this
tweet
as
“sleazy
twiAer
spam”
because
I
did
not
follow
this
account
to
receive
branded
messages
but
to
learn
more
about
how
the
celebrity
racecar
driver
Charlie
Kimball
coped
with
managing
his
diabetes
while
racing.
Although
the
adver.sed
product
is
part
of
the
story,
this
tweet
had
no
educa.onal
value
and
was
merely
a
“product
placement”
or
“reminder”
type
of
ad
that
PhRMA
says
should
not
be
used
–
at
least
on
TV.
But
if
it’s
not
OK
for
TV,
it
should
also
not
be
OK
for
social
media.
Anyway,
Novo
Nordisk
par.cipated
in
open
discussion
about
this
and
learned
–
I
haven’t
seen
any
other
tweets
like
this
since.
Listen
to
this
Pharma
Marke.ng
Talk
podcast:
“Novo
Nordisk's
Race
With
Insulin
Campaign:
It's
Not
Just
About
TwiAer”
hAp://bit.ly/PMTalk087
31. Back
in
November,
2011,
I
asked
“Will
a
Pharma
Company
Ever
Host
a
Chat
on
TwiAer?”
(hAp://bit.ly/Twchat).
I
answered
my
own
ques.on
with:
“most
pharma
companies
may
never
directly
host
or
moderate
TwiAer
chats
because
they
can
control
neither
the
audience
nor
the
message.”
So,
I
was
surprised
when
Astrazeneca
hosted
the
first
live
TwiAer
chat
session
on
February
16,
2011.
Despite
dire
predic.ons
of
"PR
failure,"
the
chat
was
a
great
success
and
proof
that
a
pharmaceu.cal
company
can
indeed
host
meaningful
TwiAer
chats.
There
were
a
few
aAempts
by
two
or
three
"malcontents"
to
"hijack"
the
conversa.on.
These
people
made
the
most
tweets
that
included
the
#rxsave
hash
tag,
but
despite
their
aAempts
to
ask
"the
tough
ques.ons"
about
off-‐label
promo.on
of
drugs
and
Seroquel
side
effects,
everyone
completely
ignored
the
hijackers
and
the
conversa.on
con.nued
as
if
these
people
were
not
even
there.
Tony
Jewell
(@tonyjewell),
Senior
Director
of
External
Communica.ons
at
AstraZeneca
US,
received
the
2nd
Pharmaguy
Social
Media
Pioneer
award
for
his
pioneering
use
of
TwiAer.
32. It
is
one
thing
to
host
a
TwiAer
chat
where
you
can
control
what
is
being
posted
by
your
representa.ve(s)
as
part
of
that
chat.
But
it
is
quite
another
problem
controlling
unauthorized
tweets
made
by
employees
without
the
knowledge
of
your
MLR
people
as
this
case
illustrates.
A
“Global
Social
Media
Policy”
doesn’t
mean
much
unless
• It
is
publicly
available
so
the
company
can
be
held
accountable
in
a
transparent
fashion,
and
• Employees
are
trained
in
the
policy,
which
should
include
sanc.ons
such
as
dismissal
for
viola.on
of
the
policy.
33. Having
social
media
principles
that
guide
how
your
employees
use
social
media
and
interact
with
the
public
online
is
a
good
first
step.
But
if
they
are
to
have
any
effect,
employees
must
be
TRAINED
to
understand
how
to
apply
the
principles
in
the
real
world.
And,
as
with
privacy
policies,
the
fact
that
employees
receive
this
training
should
be
stated
in
the
outward-‐facing
social
media
policy
that
the
company
publishes.
These
are
just
a
few
of
my
“half-‐baked”
ideas
pertaining
to
a
public
social
media
policy
for
pharmaceu.cal
companies
to
adopt.
34. Roche
is
the
only
pharmaceu.cal
company
that
has
publicly
disclosed
its
social
media
principles.
Bravo!
35. In
closing,
I
would
like
to
emphasize
that
to
implement
a
strategy
for
using
social
media
as
part
of
your
marke.ng
campaigns,
it
is
important
to
have
a
plan.
But
what
are
the
ac.on
items
for
implemen.ng
your
plan?
This
survey
asked
respondents
to
indicate
how
important
the
following
ac.on
items
are
in
implemen.ng
a
social
media
plan:
• #1:
Get
everyone
-‐
including
marke.ng,
regulatory
people,
corporate
communica.ons,
C-‐level
execs
-‐
on
board
• #2:
Become
a
dialogue
company
-‐
learn
how
to
listen
and
respond,
not
just
push
messages
out
• #3:
Have
a
sustained
vision/goal
• #4:
Train
people
who
will
be
interac.ng
directly
with
consumers
• Create
a
social
media
Tsar
posi.on
to
oversee
all
the
company's
SM
projects
to
assure
compliance
with
guidelines
• Develop
a
modera.on
strategy
• Develop
guideposts,
internal
and
external
standard
opera.ng
procedures
• Marshall
necessary
resources
-‐
use
the
best
tools
available
• Unblock
corporate
access
to
social
media
so
employees
can
monitor
and
use
applica.ons
such
as
Facebook
while
at
work
35